HC Wainwright & Co. Upgrades Innate Pharma to Buy, Announces $5 Price Target
Benzinga Newsdesk 1 year ago
NewsUpgradesPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Innate Pharma (NASDAQ:IPHA) from Neutral to Buy and announces $5 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Innate Pharma (NASDAQ:IPHA) from Neutral to Buy and announces $5 price target.